Clinical Trial Update: A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of JS207, a PD-1/VEGF bispecific antibody, in combination with chemotherapy for advanced non-squamous non-small cell lung cancer is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JS207

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Non-squamous Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING